Share Price and Basic Stock Data
Last Updated: December 19, 2025, 10:47 pm
| PEG Ratio | 0.66 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Coral Laboratories Ltd, a player in the pharmaceuticals sector, has shown a fluctuating revenue trajectory over recent quarters, indicative of its operational dynamics. In the latest quarter ending September 2023, the company reported sales of ₹23.15 Cr, a notable recovery from the previous quarter’s ₹13.55 Cr. This fluctuation is part of a broader trend; for instance, sales saw a peak of ₹28.89 Cr in March 2024, before declining to ₹18.08 Cr in December 2023. Over the fiscal year 2025, the company is expected to record sales of ₹115 Cr, up from ₹84 Cr in FY 2024. This growth reflects a rebound from previous challenges, particularly the downturn in FY 2023 when revenue dipped to ₹78 Cr. The company’s ability to navigate these ups and downs will be crucial in assessing its overall market positioning.
Profitability and Efficiency Metrics
Profitability metrics for Coral Laboratories reveal a mixed performance. The operating profit margin (OPM) stood at 11.58% in the latest assessment, which is commendable compared to previous lows, such as -18.18% in March 2023. The net profit for the year ending March 2025 is projected at ₹24 Cr, a significant jump from ₹6 Cr in FY 2023. This improvement in profitability is underpinned by a robust interest coverage ratio of 362.17x, suggesting the company is comfortably managing its negligible debt levels. However, the cash conversion cycle, which was 129 days, indicates potential inefficiencies in managing working capital. While the OPM appears strong, fluctuations in quarterly net profit—like the dip to -₹0.89 Cr in March 2023—underscore the volatility inherent in its operations.
Balance Sheet Strength and Financial Ratios
The balance sheet of Coral Laboratories reflects a healthy financial position, marked by minimal borrowings of just ₹1 Cr, which is a stark contrast to its reserves of ₹210 Cr. This low leverage, combined with a return on equity (ROE) of 13.1% and return on capital employed (ROCE) of 17.4%, suggests that the company is effectively utilizing its capital base to generate returns. The price-to-book value (P/BV) ratio stands at 1.25x, indicating that the stock is trading at a reasonable valuation relative to its net assets. Moreover, the current ratio of 7.07x indicates a strong liquidity position, allowing the company to cover its short-term obligations comfortably. However, the increase in working capital days to 140 suggests a need for Coral Laboratories to optimize its inventory and receivables management to enhance efficiency.
Shareholding Pattern and Investor Confidence
Coral Laboratories exhibits a stable shareholding pattern, with promoters holding a significant 71.51% stake, reflecting strong control and confidence in the company’s prospects. The public shareholding stands at 28.49%, with foreign institutional investors (FIIs) currently holding a negligible stake of 0.00%. This lack of foreign investment may signal a perception of risk or a need for further engagement with global investors. Notably, the number of shareholders has increased from 4,046 in March 2023 to 4,286 in September 2025, indicating growing interest among retail investors. This confidence is crucial, especially as the company seeks to stabilize its revenue and improve profitability, thereby enhancing shareholder value in the long run.
Outlook, Risks, and Final Insight
The outlook for Coral Laboratories is cautiously optimistic, driven by improving sales and profitability metrics. However, there are notable risks to consider. The company’s revenue has been inconsistent, with significant fluctuations in quarterly results that could deter potential investors seeking stability. Additionally, the high cash conversion cycle points to inefficiencies in operations that could affect liquidity and profitability in the future. On the upside, the strong promoter backing and low debt levels provide a solid foundation for growth. Investors should weigh these strengths against potential risks, particularly in the context of market volatility and operational challenges. As Coral Laboratories navigates this landscape, its ability to maintain momentum in sales growth and operational efficiency will be critical in determining its long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,165.63 Cr | 1,151.80 | 52.58 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.25 | 25.70 | 24.73 | 11.44 | 13.55 | 23.15 | 18.08 | 28.89 | 31.66 | 32.23 | 22.99 | 28.13 | 18.82 |
| Expenses | 15.52 | 21.39 | 23.88 | 13.52 | 11.81 | 17.00 | 15.98 | 22.64 | 20.92 | 25.72 | 16.67 | 25.44 | 16.64 |
| Operating Profit | 0.73 | 4.31 | 0.85 | -2.08 | 1.74 | 6.15 | 2.10 | 6.25 | 10.74 | 6.51 | 6.32 | 2.69 | 2.18 |
| OPM % | 4.49% | 16.77% | 3.44% | -18.18% | 12.84% | 26.57% | 11.62% | 21.63% | 33.92% | 20.20% | 27.49% | 9.56% | 11.58% |
| Other Income | 2.03 | 2.21 | 1.54 | 1.16 | 1.29 | 1.81 | 1.37 | 2.00 | 1.56 | 2.54 | 2.52 | 1.71 | 2.05 |
| Interest | 0.10 | 0.11 | 0.11 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.02 | 0.04 | 0.06 |
| Depreciation | 0.50 | 0.50 | 0.50 | 0.68 | 0.55 | 0.44 | 0.49 | 0.50 | 0.49 | 0.51 | 0.50 | 0.51 | 0.45 |
| Profit before tax | 2.16 | 5.91 | 1.78 | -1.62 | 2.48 | 7.52 | 2.98 | 7.75 | 11.78 | 8.53 | 8.32 | 3.85 | 3.72 |
| Tax % | 26.39% | 17.26% | 51.69% | -45.06% | 26.21% | 20.21% | 27.52% | 25.16% | 25.21% | 25.21% | 26.08% | 26.49% | 31.18% |
| Net Profit | 1.59 | 4.89 | 0.86 | -0.89 | 1.84 | 6.00 | 2.16 | 5.79 | 8.80 | 6.38 | 6.14 | 2.83 | 2.56 |
| EPS in Rs | 4.45 | 13.69 | 2.41 | -2.49 | 5.15 | 16.79 | 6.05 | 16.21 | 24.63 | 17.86 | 17.19 | 7.92 | 7.17 |
Last Updated: August 19, 2025, 8:45 pm
Below is a detailed analysis of the quarterly data for Coral Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 18.82 Cr.. The value appears to be declining and may need further review. It has decreased from 28.13 Cr. (Mar 2025) to 18.82 Cr., marking a decrease of 9.31 Cr..
- For Expenses, as of Jun 2025, the value is 16.64 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 25.44 Cr. (Mar 2025) to 16.64 Cr., marking a decrease of 8.80 Cr..
- For Operating Profit, as of Jun 2025, the value is 2.18 Cr.. The value appears to be declining and may need further review. It has decreased from 2.69 Cr. (Mar 2025) to 2.18 Cr., marking a decrease of 0.51 Cr..
- For OPM %, as of Jun 2025, the value is 11.58%. The value appears strong and on an upward trend. It has increased from 9.56% (Mar 2025) to 11.58%, marking an increase of 2.02%.
- For Other Income, as of Jun 2025, the value is 2.05 Cr.. The value appears strong and on an upward trend. It has increased from 1.71 Cr. (Mar 2025) to 2.05 Cr., marking an increase of 0.34 Cr..
- For Interest, as of Jun 2025, the value is 0.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.04 Cr. (Mar 2025) to 0.06 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.45 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.51 Cr. (Mar 2025) to 0.45 Cr., marking a decrease of 0.06 Cr..
- For Profit before tax, as of Jun 2025, the value is 3.72 Cr.. The value appears to be declining and may need further review. It has decreased from 3.85 Cr. (Mar 2025) to 3.72 Cr., marking a decrease of 0.13 Cr..
- For Tax %, as of Jun 2025, the value is 31.18%. The value appears to be increasing, which may not be favorable. It has increased from 26.49% (Mar 2025) to 31.18%, marking an increase of 4.69%.
- For Net Profit, as of Jun 2025, the value is 2.56 Cr.. The value appears to be declining and may need further review. It has decreased from 2.83 Cr. (Mar 2025) to 2.56 Cr., marking a decrease of 0.27 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.17. The value appears to be declining and may need further review. It has decreased from 7.92 (Mar 2025) to 7.17, marking a decrease of 0.75.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 59 | 77 | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 115 | 89 |
| Expenses | 41 | 47 | 60 | 72 | 77 | 79 | 65 | 81 | 67 | 74 | 67 | 89 | 73 |
| Operating Profit | 10 | 12 | 16 | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 | 16 |
| OPM % | 20% | 21% | 21% | 24% | 17% | 14% | 8% | 16% | 11% | 5% | 19% | 23% | 18% |
| Other Income | 1 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 6 | 7 | 6 | 8 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 12 | 17 | 25 | 18 | 16 | 9 | 18 | 12 | 8 | 21 | 32 | 23 |
| Tax % | 21% | 22% | 29% | 34% | 31% | 34% | 22% | 23% | 24% | 22% | 24% | 26% | |
| Net Profit | 8 | 10 | 12 | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 24 | 17 |
| EPS in Rs | 22.03 | 26.79 | 34.71 | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 67.63 | 48.57 |
| Dividend Payout % | 9% | 9% | 9% | 11% | 6% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.00% | 20.00% | 33.33% | -25.00% | -16.67% | -30.00% | 100.00% | -35.71% | -33.33% | 166.67% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -5.00% | 13.33% | -58.33% | 8.33% | -13.33% | 130.00% | -135.71% | 2.38% | 200.00% | -116.67% |
Coral Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 28% |
| 3 Years: | 44% |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 9% |
| 3 Years: | 21% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:40 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 47 | 56 | 67 | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 198 | 210 |
| Borrowings | 0 | 1 | 0 | 2 | 2 | 1 | 6 | 6 | 6 | 0 | 0 | 4 | 1 |
| Other Liabilities | 10 | 12 | 19 | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 25 | 19 |
| Total Liabilities | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 233 |
| Fixed Assets | 20 | 19 | 18 | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 | 24 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 14 |
| Investments | 1 | 1 | 5 | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 52 | 57 |
| Other Assets | 40 | 52 | 67 | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 152 | 138 |
| Total Assets | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 233 |
Below is a detailed analysis of the balance sheet data for Coral Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Reserves, as of Sep 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 210.00 Cr., marking an increase of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing). It has decreased from 25.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 233.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 229.00 Cr. (Mar 2025) to 233.00 Cr., marking an increase of 4.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 12.00 Cr..
- For Investments, as of Sep 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 52.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 138.00 Cr.. The value appears to be declining and may need further review. It has decreased from 152.00 Cr. (Mar 2025) to 138.00 Cr., marking a decrease of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 233.00 Cr.. The value appears strong and on an upward trend. It has increased from 229.00 Cr. (Mar 2025) to 233.00 Cr., marking an increase of 4.00 Cr..
Notably, the Reserves (210.00 Cr.) exceed the Borrowings (1.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 10.00 | 11.00 | 16.00 | 21.00 | 13.00 | 11.00 | -1.00 | 10.00 | 2.00 | 4.00 | 16.00 | 22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 109 | 152 | 132 | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 | 107 |
| Inventory Days | 97 | 110 | 110 | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 | 68 |
| Days Payable | 61 | 66 | 80 | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 | 46 |
| Cash Conversion Cycle | 145 | 196 | 162 | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 | 129 |
| Working Capital Days | 158 | 194 | 179 | 164 | 161 | 171 | 241 | 178 | 222 | 221 | 183 | 140 |
| ROCE % | 21% | 22% | 27% | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% | 17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| Diluted EPS (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| Cash EPS (Rs.) | 73.24 | 49.72 | 24.14 | 30.89 | 43.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 |
| Dividend / Share (Rs.) | 1.50 | 2.00 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 321.91 | 234.17 | 218.66 | 211.64 | 270.30 |
| PBDIT / Share (Rs.) | 98.94 | 64.02 | 29.97 | 36.47 | 54.91 |
| PBIT / Share (Rs.) | 93.31 | 58.49 | 23.87 | 30.89 | 49.37 |
| PBT / Share (Rs.) | 90.89 | 58.03 | 23.02 | 33.19 | 49.25 |
| Net Profit / Share (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| PBDIT Margin (%) | 30.73 | 27.33 | 13.70 | 17.23 | 20.31 |
| PBIT Margin (%) | 28.98 | 24.97 | 10.91 | 14.59 | 18.26 |
| PBT Margin (%) | 28.23 | 24.78 | 10.53 | 15.67 | 18.21 |
| Net Profit Margin (%) | 21.00 | 18.87 | 8.25 | 11.96 | 14.03 |
| Return on Networth / Equity (%) | 12.00 | 8.89 | 4.16 | 5.79 | 9.91 |
| Return on Capital Employeed (%) | 16.30 | 11.55 | 5.24 | 6.71 | 12.61 |
| Return On Assets (%) | 10.52 | 7.67 | 3.69 | 4.76 | 8.09 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.03 | 0.04 |
| Asset Turnover Ratio (%) | 0.52 | 0.44 | 0.42 | 0.42 | 0.61 |
| Current Ratio (X) | 7.07 | 6.18 | 10.42 | 5.13 | 3.99 |
| Quick Ratio (X) | 6.68 | 5.57 | 9.36 | 4.41 | 3.21 |
| Inventory Turnover Ratio (X) | 9.19 | 2.87 | 2.68 | 1.92 | 2.39 |
| Dividend Payout Ratio (NP) (%) | 2.95 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 2.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 97.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 97.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 362.17 | 114356.50 | 31.63 | 92.33 | 461.63 |
| Interest Coverage Ratio (Post Tax) (X) | 256.38 | 79763.50 | 19.93 | 58.31 | 319.93 |
| Enterprise Value (Cr.) | 174.27 | 71.40 | 41.37 | 59.77 | 86.55 |
| EV / Net Operating Revenue (X) | 1.52 | 0.85 | 0.52 | 0.79 | 0.89 |
| EV / EBITDA (X) | 4.93 | 3.12 | 3.86 | 4.59 | 4.41 |
| MarketCap / Net Operating Revenue (X) | 2.18 | 1.59 | 1.05 | 1.21 | 1.19 |
| Retention Ratios (%) | 97.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 1.25 | 0.74 | 0.52 | 0.58 | 0.84 |
| Price / Net Operating Revenue (X) | 2.18 | 1.59 | 1.05 | 1.21 | 1.19 |
| EarningsYield | 0.09 | 0.11 | 0.07 | 0.09 | 0.11 |
After reviewing the key financial ratios for Coral Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 22, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 21) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
- For Diluted EPS (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
- For Cash EPS (Rs.), as of Mar 22, the value is 73.24. This value is within the healthy range. It has increased from 49.72 (Mar 21) to 73.24, marking an increase of 23.52.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 563.19. It has increased from 496.83 (Mar 21) to 563.19, marking an increase of 66.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 563.19. It has increased from 496.83 (Mar 21) to 563.19, marking an increase of 66.36.
- For Dividend / Share (Rs.), as of Mar 22, the value is 1.50. This value is within the healthy range. It has decreased from 2.00 (Mar 21) to 1.50, marking a decrease of 0.50.
- For Revenue From Operations / Share (Rs.), as of Mar 22, the value is 321.91. It has increased from 234.17 (Mar 21) to 321.91, marking an increase of 87.74.
- For PBDIT / Share (Rs.), as of Mar 22, the value is 98.94. This value is within the healthy range. It has increased from 64.02 (Mar 21) to 98.94, marking an increase of 34.92.
- For PBIT / Share (Rs.), as of Mar 22, the value is 93.31. This value is within the healthy range. It has increased from 58.49 (Mar 21) to 93.31, marking an increase of 34.82.
- For PBT / Share (Rs.), as of Mar 22, the value is 90.89. This value is within the healthy range. It has increased from 58.03 (Mar 21) to 90.89, marking an increase of 32.86.
- For Net Profit / Share (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
- For PBDIT Margin (%), as of Mar 22, the value is 30.73. This value is within the healthy range. It has increased from 27.33 (Mar 21) to 30.73, marking an increase of 3.40.
- For PBIT Margin (%), as of Mar 22, the value is 28.98. This value exceeds the healthy maximum of 20. It has increased from 24.97 (Mar 21) to 28.98, marking an increase of 4.01.
- For PBT Margin (%), as of Mar 22, the value is 28.23. This value is within the healthy range. It has increased from 24.78 (Mar 21) to 28.23, marking an increase of 3.45.
- For Net Profit Margin (%), as of Mar 22, the value is 21.00. This value exceeds the healthy maximum of 10. It has increased from 18.87 (Mar 21) to 21.00, marking an increase of 2.13.
- For Return on Networth / Equity (%), as of Mar 22, the value is 12.00. This value is below the healthy minimum of 15. It has increased from 8.89 (Mar 21) to 12.00, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 22, the value is 16.30. This value is within the healthy range. It has increased from 11.55 (Mar 21) to 16.30, marking an increase of 4.75.
- For Return On Assets (%), as of Mar 22, the value is 10.52. This value is within the healthy range. It has increased from 7.67 (Mar 21) to 10.52, marking an increase of 2.85.
- For Total Debt / Equity (X), as of Mar 22, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 21) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 22, the value is 0.52. It has increased from 0.44 (Mar 21) to 0.52, marking an increase of 0.08.
- For Current Ratio (X), as of Mar 22, the value is 7.07. This value exceeds the healthy maximum of 3. It has increased from 6.18 (Mar 21) to 7.07, marking an increase of 0.89.
- For Quick Ratio (X), as of Mar 22, the value is 6.68. This value exceeds the healthy maximum of 2. It has increased from 5.57 (Mar 21) to 6.68, marking an increase of 1.11.
- For Inventory Turnover Ratio (X), as of Mar 22, the value is 9.19. This value exceeds the healthy maximum of 8. It has increased from 2.87 (Mar 21) to 9.19, marking an increase of 6.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 22, the value is 2.95. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 21) to 2.95, marking an increase of 2.95.
- For Dividend Payout Ratio (CP) (%), as of Mar 22, the value is 2.73. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 21) to 2.73, marking an increase of 2.73.
- For Earning Retention Ratio (%), as of Mar 22, the value is 97.05. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 21) to 97.05, marking an increase of 97.05.
- For Cash Earning Retention Ratio (%), as of Mar 22, the value is 97.27. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 21) to 97.27, marking an increase of 97.27.
- For Interest Coverage Ratio (X), as of Mar 22, the value is 362.17. This value is within the healthy range. It has decreased from 114,356.50 (Mar 21) to 362.17, marking a decrease of 113,994.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 22, the value is 256.38. This value is within the healthy range. It has decreased from 79,763.50 (Mar 21) to 256.38, marking a decrease of 79,507.12.
- For Enterprise Value (Cr.), as of Mar 22, the value is 174.27. It has increased from 71.40 (Mar 21) to 174.27, marking an increase of 102.87.
- For EV / Net Operating Revenue (X), as of Mar 22, the value is 1.52. This value is within the healthy range. It has increased from 0.85 (Mar 21) to 1.52, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 22, the value is 4.93. This value is below the healthy minimum of 5. It has increased from 3.12 (Mar 21) to 4.93, marking an increase of 1.81.
- For MarketCap / Net Operating Revenue (X), as of Mar 22, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 21) to 2.18, marking an increase of 0.59.
- For Retention Ratios (%), as of Mar 22, the value is 97.04. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 21) to 97.04, marking an increase of 97.04.
- For Price / BV (X), as of Mar 22, the value is 1.25. This value is within the healthy range. It has increased from 0.74 (Mar 21) to 1.25, marking an increase of 0.51.
- For Price / Net Operating Revenue (X), as of Mar 22, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 21) to 2.18, marking an increase of 0.59.
- For EarningsYield, as of Mar 22, the value is 0.09. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 21) to 0.09, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Coral Laboratories Ltd:
- Net Profit Margin: 21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.3% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 256.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 6.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 9.23 (Industry average Stock P/E: 43.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3B, Patanwala Compound, Mumbai Maharashtra 400086 | cs@corallab.com http://www.corallab.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajendrasinh Rana | Director |
| Mr. Girish M Dhameja | Whole Time Director |
| Mrs. Sushma Kadkade | Director & CFO |
| Ms. Pooja Hindia | Independent Director |
| Dr. Saurabh Shah | Independent Director |
| Mr. Malay Doshi | Independent Director |
FAQ
What is the intrinsic value of Coral Laboratories Ltd?
Coral Laboratories Ltd's intrinsic value (as of 19 December 2025) is 578.42 which is 26.85% higher the current market price of 456.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 163 Cr. market cap, FY2025-2026 high/low of 859/431, reserves of ₹210 Cr, and liabilities of 233 Cr.
What is the Market Cap of Coral Laboratories Ltd?
The Market Cap of Coral Laboratories Ltd is 163 Cr..
What is the current Stock Price of Coral Laboratories Ltd as on 19 December 2025?
The current stock price of Coral Laboratories Ltd as on 19 December 2025 is 456.
What is the High / Low of Coral Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Coral Laboratories Ltd stocks is 859/431.
What is the Stock P/E of Coral Laboratories Ltd?
The Stock P/E of Coral Laboratories Ltd is 9.23.
What is the Book Value of Coral Laboratories Ltd?
The Book Value of Coral Laboratories Ltd is 596.
What is the Dividend Yield of Coral Laboratories Ltd?
The Dividend Yield of Coral Laboratories Ltd is 0.33 %.
What is the ROCE of Coral Laboratories Ltd?
The ROCE of Coral Laboratories Ltd is 17.4 %.
What is the ROE of Coral Laboratories Ltd?
The ROE of Coral Laboratories Ltd is 13.1 %.
What is the Face Value of Coral Laboratories Ltd?
The Face Value of Coral Laboratories Ltd is 10.0.